Primary effusion lymphoma (PEL) is an aggressive non‐Hodgkin B cell lymphoma associated to Kaposi's sarcoma‐associated herpes-virus (KSHV), for which there is not an optimal therapy yet. Indeed, cyclophosphamide, doxorubicin, vincristine, and prednisone chemo-therapy, currently used as first‐line therapy, induces only a partial remission of disease in less than half percent of PEL patients. Bortezomib (BZ) is a proteasome inhibitor mainly used for the treatment of Multiple Myeloma (MM). Here we investigated if Chloroquine supplementation could potentiate the outcome of BZ treatment in vivo, in NSG mouse model.
New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
D'Orazi, Gabriella;
2024-01-01
Abstract
Primary effusion lymphoma (PEL) is an aggressive non‐Hodgkin B cell lymphoma associated to Kaposi's sarcoma‐associated herpes-virus (KSHV), for which there is not an optimal therapy yet. Indeed, cyclophosphamide, doxorubicin, vincristine, and prednisone chemo-therapy, currently used as first‐line therapy, induces only a partial remission of disease in less than half percent of PEL patients. Bortezomib (BZ) is a proteasome inhibitor mainly used for the treatment of Multiple Myeloma (MM). Here we investigated if Chloroquine supplementation could potentiate the outcome of BZ treatment in vivo, in NSG mouse model.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Hematological Oncology - 2024.pdf
Solo gestori archivio
Descrizione: file finale
Tipologia:
PDF editoriale
Dimensione
339.22 kB
Formato
Adobe PDF
|
339.22 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.